AB Science announces publication of a significant response case with masitinib in a patient with c-KIT-mutated metastatic melanoma a patient with of c-KIT-mutated metastatic melanoma
December 02, 2015 12:53 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Paris, 2 December 2015, 7pm AB Science...
AB Science Announces Positive Top-Line Results from Phase 3 Trial of Masitinib in Adults with Severe Systemic Mastocytosis
November 30, 2015 12:25 ET
|
AB Science
PARIS, Nov. 30, 2015 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase...
AB Science Announces Positive Top-Line Results from Phase 3 Trial of Masitinib in Adults with Severe Systemic Mastocytosis
November 30, 2015 12:20 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Paris, 30 November 2015, 6.15pm AB Science...
AB Science annonce le succès sur le critère principal et les critères secondaires de l'étude de phase 3 du masitinib dans le traitement de la mastocystose systémique sévère chez l'adulte
November 30, 2015 12:20 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Paris, 30 novembre 2015, 18h15 AB Science...
AB Science : Information mensuelle relative au nombre total de droits de vote et d'actions
November 06, 2015 09:39 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
AB SCIENCE S.A.Société Anonyme au capital de...
AB Science : levée de l'insu des résultats de l'étude de phase 3 dans la mastocytose prévue pour novembre 2015
October 06, 2015 12:27 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Paris, 6 octobre 2015, 18h Les...
AB Science: unblinding of phase 3 mastocytosis study data planned for November 2015
October 06, 2015 12:27 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Paris, 06 October 2015, 6pm Simulations...
AB Science announces cessation of its rheumatoid arthritis study in order to focus on clinical studies with a probability of success greater than 50%
September 21, 2015 12:06 ET
|
AB Science
PARIS, Sept. 21, 2015 (GLOBE NEWSWIRE) -- AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors...
AB Science announces cessation of its rheumatoid arthritis study in order to focus on clinical studies with a probability of success greater than 50%
September 21, 2015 11:59 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Paris, 21 September 2015, 17h45 AB Science...
AB Science annonce l'arrêt de l'étude clinique dans la polyarthrite rhumatoïde afin de se concentrer sur les études ayant une probabilité de succès supérieure à 50%
September 21, 2015 11:59 ET
|
AB Science
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Paris, 21 septembre 2015, 17h45 AB Science...